Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29837419 | 1.00 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| Ammonia Solution, Strong SCHEMBL28752425 | 0.98 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8035636 | 0.84 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19886485 | 0.84 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2002833 | 0.82 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23052 | 0.82 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29096230 | 0.82 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14183054 | 0.81 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12180454 | 0.81 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13256249 | 0.81 | NQO1 (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120000585-A | Novel drug-assisted precursor micelle preparation and production method thereof | 酰莱(合肥)生命科学研发有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119999908-A | Novel oil-soluble precursor micelle preparation and production method thereof | 酰莱(合肥)生命科学研发有限公司 | 2025-05-16 | — | — | CN | claimed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| EP-1915149-B1 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2018-10-10 | — | — | EP | claimed |
| CN-108530273-A | A kind of synthetic method of 2,4- dimethoxy-toluenes base -4- propyl diphenol | 武汉桀升生物科技有限公司 | 2018-09-14 | — | — | CN | claimed |
| CN-107530259-A | Method using acid amides, acid or ester C glycosides derivatives processing keratin material and the cosmetic composition containing them | 莱雅公司 | 2018-01-02 | — | — | CN | claimed |
| CN-107011167-A | The method for preparing the angelate of ingenol 3 | 利奥实验室有限公司 | 2017-08-04 | — | — | CN | claimed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | claimed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | claimed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | claimed |
| US-20050234053-A1 | 9-oxo-3,4,6,9-tetrahydro-2H-[1,4]-(oxazino, thiazino, or pyrazino)[3,2-b][1,8]naphthyridine-8-carboxylic acids; fish or mammals; bacterial protein biosynthesis inhibitors | ABBVIE INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005075477-A1 | ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | claimed |
| US-20050159423-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | claimed |
| EP-1501846-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| EP-0986560-B1 | PYRROLO 2,1,5-CD]INDOLIZINE DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | KAROBIO AB (SE) | 2004-03-24 | — | — | EP | claimed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | claimed |
| WO-2003093289-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | CA12 1642/4885CA1 3196/4885CA2 3048/4885 |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | CA12 4321/4885CA1 4144/4885CA2 3682/4885 |
| US-20050159423-A1 | Antibacterial compounds | MRPL21, FDPS, PGLS | CA12 4278/4885CA1 3427/4885CA2 2642/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | CA12 299/4885CA1 140/4885CA2 458/4885 |
| US-20050234053-A1 | 9-oxo-3,4,6,9-tetrahydro-2H-[1,4]-(oxazino, thiazino, or pyrazino)[3,2-b][1,8]naphthyridine-8-carboxylic acids; fish or mammals; bacterial protein biosynthesis inhibitors | DHPS, COASY, PNPO | CA12 4805/4885CA1 4449/4885CA2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.